Want to see PROK full AI Analyst Report?
Top Page
ProKidney
(NASDAQ:PROK)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▲(0.00% Upside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by very weak financial performance (minimal revenue, large losses, and substantial cash burn implying continued financing needs). Technicals are mixed—some near-term stabilization but still below key longer-term moving averages. Corporate updates around Phase 3 progress and regulatory alignment provide a positive offset, while valuation remains unattractive on a negative P/E.
Positive Factors
Regulatory Alignment
FDA recognition of eGFR slope as an acceptable surrogate endpoint materially raises the program's regulatory clarity. This creates a defined accelerated approval path that can shorten time-to-market and reduce late-stage regulatory risk versus unclear endpoint strategies.
Negative Factors
High Cash Burn
Sustained multi-hundred-million dollar cash outflows mean the company cannot self-fund development long-term. Persistent burn creates structural dependency on external capital, raising dilution risk and constraining strategic optionality ahead of potential commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Alignment
FDA recognition of eGFR slope as an acceptable surrogate endpoint materially raises the program's regulatory clarity. This creates a defined accelerated approval path that can shorten time-to-market and reduce late-stage regulatory risk versus unclear endpoint strategies.
Read all positive factors
ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$495.38M
Dividend YieldN/A
Average Volume (3M)1.38M
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue Growth190.52%
EPS Growth12.60%
CountryUS
Employees231
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding205,199,700
10 Day Avg. Volume1,177,473
30 Day Avg. Volume1,376,340
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside283.33% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$511.14K
ProKidney Business Overview & Revenue Model
Company Description
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derive...
How the Company Makes Money
As a clinical-stage biotechnology company, ProKidney does not have publicly established, recurring product sales revenue from approved therapies; therefore, revenue is primarily expected to come in the future if its lead candidate (rilparencel/REA...
ProKidney Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 818.00K | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.07M | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -160.75M | -144.62M | -158.49M | -125.59M | -143.99M | -53.12M |
| Net Income | -86.71M | -68.99M | -61.19M | -35.47M | -108.03M | -55.15M |
Balance Sheet | ||||||
| Total Assets | 249.02M | 335.57M | 441.07M | 420.55M | 518.00M | 40.30M |
| Cash, Cash Equivalents and Short-Term Investments | 181.56M | 270.02M | 358.29M | 362.95M | 490.25M | 20.56M |
| Total Debt | 2.39M | 4.04M | 3.24M | 4.41M | 2.40M | 1.33M |
| Total Liabilities | 26.18M | 34.78M | 39.44M | 29.22M | 13.06M | 13.38M |
| Stockholders Equity | 222.84M | -1.01B | -994.95M | -1.10B | -1.10B | 26.92M |
Cash Flow | ||||||
| Free Cash Flow | -155.90M | -135.31M | -155.86M | -124.27M | -78.94M | -55.49M |
| Operating Cash Flow | -141.17M | -120.12M | -126.35M | -90.07M | -77.09M | -50.30M |
| Investing Cash Flow | 104.74M | 103.97M | 20.41M | -329.98M | -1.74M | -5.19M |
| Financing Cash Flow | 26.35M | 25.57M | 144.41M | -9.55M | 548.52M | 71.47M |
ProKidney Technical Analysis
Neutral
1.50
Price Trends
1.71
Negative
1.78
Negative
2.06
Negative
Market Momentum
-0.02
Negative
54.16
Neutral
80.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Neutral. The current price of 1.5 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.71, and below the 200-day MA of 2.06, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 80.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PROK.
ProKidney Risk Analysis
ProKidney disclosed 91 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProKidney Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.30B | -23.39 | 121.52% | ― | 100.27% | 39.90% | |
59 Neutral | $2.65B | -7.50 | -76.09% | ― | -58.40% | -31.99% | |
56 Neutral | $451.61M | -5.71 | -58.82% | ― | ― | 29.97% | |
55 Neutral | $4.33B | -12.70 | -42.27% | ― | 23.86% | 19.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $691.70M | -6.70 | 25.70% | ― | 110.16% | 73.04% | |
45 Neutral | $495.38M | -2.96 | 7.40% | ― | 190.52% | 12.60% |
* Healthcare Sector Average
PROK
ProKidney
1.69
-0.57
-25.06%
RZLT
Rezolute
4.68
-1.26
-21.21%
URGN
Urogen Pharma
46.31
28.07
153.89%
PHAT
Phathom Pharmaceuticals
8.57
-1.71
-16.63%
RLAY
Relay Therapeutics
19.94
16.69
513.54%
NRIX
Nurix Therapeutics
25.88
16.23
168.19%
ProKidney Corporate Events
Executive/Board ChangesShareholder Meetings
ProKidney shareholders reaffirm board and auditor at 2026 meeting
Positive
May 29, 2026
On May 28, 2026, ProKidney Corp. held its 2026 Annual Meeting of Stockholders, at which shareholders elected three directors, William F. Doyle, Alan M. Lotvin, M.D., and Brian J.G. Pereira, to three-year terms ending at the 2029 annual meeting. At...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
Positive
May 15, 2026
On May 15, 2026, ProKidney reported first-quarter 2026 results and business updates, highlighting progress in its pivotal Phase 3 REGEN-006 (PROACT 1) trial of rilparencel for advanced CKD in patients with diabetes. The company said enrollment for...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.